New People Same DNA

New People Same DNA

Early Wednesday morning Abbott will kick off first quarter’s earnings season. Traditionally the first quarter is the slowest for diabetes tech and we don’t expect this to change. What is changing and worth paying attention to is the slowing pace of Libre sales. Now some of this is frankly anticipated as Libre has grown into a $6 billion franchise. But signs of Abbott’s past are remerging, and this does not bode well for the future.

Back in February of 2004 Abbott acquired BGM maker Therasense for $1.2 Billion. This was after they ran another BGM acquisition . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.